Last reviewed · How we verify
NCT06929338
xDRIVE in Metastatic Colorectal Cancer
trial testing Functional precision medicine in Metastatic Colon Adenocarcinoma in 30 participants. Not yet recruiting.
30 June 2026
Quick facts
| Lead sponsor | First Ascent Biomedical Inc. |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 15 September 2025 |
| Primary completion | 30 June 2026 |
| Estimated completion | 30 June 2027 |
Drugs / interventions tested
- Functional precision medicine
Conditions studied
- Metastatic Colon Adenocarcinoma — all drugs for Metastatic Colon Adenocarcinoma →
- Metastatic Colon Cancer — all drugs for Metastatic Colon Cancer →
- Metastatic Rectal Adenocarcinoma — all drugs for Metastatic Rectal Adenocarcinoma →
- Metastatic Rectal Carcinoma — all drugs for Metastatic Rectal Carcinoma →
Sponsor
First Ascent Biomedical Inc.
Who can join
18 and older, any sex, with Metastatic Colon Adenocarcinoma or Metastatic Colon Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aims to evaluate the clinical utility of the xDRIVE functional precision medicine + artificial intelligence (AI) platform in predicting treatment response for metastatic colorectal cancer (mCRC). The primary objective is to assess xDRIVE's accuracy in forecasting clinical benefit from standard-of-care (SOC) therapies, with a target of ≥80% accuracy in 25 participants. Achieving this threshold would provide sufficient statistical power to reject the null hypothesis of ≤50% accuracy. The secondary goal is to determine the feasibility of utilizing xDRIVE for timely treatment recommendations. Success will be defined by the ability to provide recommendations within four weeks for at least 64% of patients, ensuring clinical applicability. Additionally, the study includes an exploratory objective to examine oncologists' perspectives on integrating xDRIVE into clinical decision-making. This will be achieved through a post-hoc survey assessing physician experiences with the precision oncology platform.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06929338
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metastatic Colon Adenocarcinoma
Currently open trials in the same condition.
- NCT05627635 — FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite · Phase 1, PHASE2 · active not recruiting
- NCT05308446 — Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer T · Phase 2 · active not recruiting
- NCT04616183 — LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorec · Phase 1, PHASE2 · active not recruiting
- NCT04599140 — SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC · Phase 1, PHASE2 · active not recruiting
- NCT03992456 — Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal · Phase 2 · active not recruiting
Other First Ascent Biomedical Inc. trials
Trials by the same sponsor.
- NCT07167381 — xDRIVE for Florida-based Cancer Patients · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06929338 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Ascent Biomedical Inc.
- Last refreshed: 16 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06929338.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing